BASIC AND CLINICAL STUDIES ON CEFOXITIN, A NEW ANTIBIOTIC AGENT, RELATED TO THE TREATMENT OF RESPIRATORY INFECTIONS
スポンサーリンク
概要
- 論文の詳細を見る
Cefoxitin (CFX), a new derivative of cephamycin C compounds, was examined basically and clinically in patients with respiratory infectious diseases, and the following results were obtained:<BR>1) Antibacterial activity: Minimum inhibitory concentrations of CFX were determined according to the standard method of the Japan Society of Chemotherapy on 769 strains in total including 21 strains preserved in our department as standard strain and 748 strains isolated from various clinical materials (<I>Staph. aureus</I> 81, <I>Salmonella species</I> 36, <I>Citrobacter freundii</I> 53, <I>Shigella</I> 44, <I>Escherichia coli</I> 81, <I>Klebsiella aerogenes</I> 77, <I>Enterobacter aerogenes</I> 43, <I>Ent. cloacae</I> 43, <I>Serratia marcescens</I> 81, <I>Proteus mirabilis</I> 53, <I>Pr. vulgaris</I> 25, <I>Pr. rettgeri</I> 22, <I>Pr. inconstans</I> 8, <I>Morganella morganii</I> 42 and <I>Pseudomonas aeruginosa</I> 59).<BR>In comparing these results with those of cefazolin (CEZ), CEZ was more effective than CFX against <I>Staph. aureus, Salmonella</I> and most of <I>Escherichia coli</I> and <I>Kl. aerogenes</I>, but CFX was stronger in antibacterial activity than CEZ against Proteus group and Morganella. Although CFX also had activity against <I>Serratia marcescens</I>, the MIC showed a relatively high level. CFX was not effective against <I>Ps. aeruginosa</I>, the same as CEZ.<BR>2) Blood level in human: In three cases, CFX was injected intravenously by drip infusion for 2 hours at a dose of 4g with 5% glucose 500 ml, and blood concentrations of the drug were measured. A peak value of 99.3μg/ml was shown at the termination of the drip infusion, and no activity was noticed in 2 cases at 6 hours after the drip infusion.<BR>3) Clinical results on respiratory infections: CFX was given intravenously by drip infusion at a dose of 4g once daily to 5 cases and twice a day to one case of respiratory infectious diseases. Results obtained were excellent in one case and good in one case of bacterial pneumonia and fair in one case of bacterial pneumonia with primary lung cancer. No improvement was shown in the remaining 3 cases with bronchiectasis, pneumonia with lung cancer and chronic bronchitis.<BR>In one case, <I>Serratia marcescens</I> disappeared in the sputum after the treatment. CFX was not effective against <I>Haemophillus influenzae</I> infections in chronic bronchitis.<BR>Side effects: An elevation of S-GOT and S-GPT was observed in one patient, though the levels returned to normal after drug was changed to CET and CEX.
- 公益社団法人 日本化学療法学会の論文
公益社団法人 日本化学療法学会 | 論文
- DISPOSITION OF 7432-8 IN RATS (I)
- CLINICAL STUDIES ON T-1220 IN SURGICAL CASES
- CLINICAL STUDIES OF PIVALOYLOXYMETHYL D-α-AMINOBENZYL-PENICILLINATE HYDROCHLORIDE IN SURGICAL INFECTIONS
- STUDIES ON AC-1370
- Primary treatment with a combination of cyclophosphamide, vincristine, and dacarbazine for recurrent malignant pheochromocytoma: A case report.